FDA Clears Merck’s Keytruda and Keytruda Qlex for Select Ovarian Cancer Patients
The U.S. Food and Drug Administration has approved Merck’s pembrolizumab (Keytruda) and pembrolizumab with berahyaluronidase alfa-pmph (Keytruda Qlex) for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) and who have received one or two prior systemic treat…